Improving the viability of Pseudo-islets for efficient insulin production research area anti-tumor

3^rd Global summit on Oncology and Cancer

May 06-07, 2019 Tokyo, Japan

Mohammadali Soleimani Damaneh

University of Chinese Academy of Sciences, Beijing

Posters & Accepted Abstracts: J Cancer Sci Ther

Abstract :

Recently, many efforts have been made to find new BRD4 inhibitors, that is why we have to understand and develop a New Anti-Cancer Agents (NACAs) for BRD4 inhibition, then we have been working in this area for several years and newly we figured out some results and finally, a new BRD4 inhibitor Hjp-b-171 was derived from one PLK1-BRD4 dual inhibitor BI-2536. The most important is that Hjp-b-171 has potential anti-tumor activity and it selectively blocks the BET. Actually, the anti-tumor effect of Hjp-b-171 compound was effective approvingly as much better than positive control (+)-JQ-1 and OTX- 015, according to results including both in vitro and in vivo antitumor experiments. In conclusion, this research showed that a new BRD4 inhibitor, Hjp-b-171, is more effective in inhibiting cell proliferation and potently down-regulates several common oncogenes, including c-MYC. metabolism and pharmacokinetics data identified Hjp-b-171 has the potential to become one candidate drug as a BRD4 inhibitor.

Biography :

E-mail: 2016b8012307005@simm.ac.cn